CD19+ cells could be detected in all 38 tumor samples and on average made up 8.9% of the CD45+ lymphocytic infiltrate of colorectal cancers compared to 5.1% of the CD45+ PBMCs of CRC patients (p<0,005, Fig. 1A). This evidence concerns the gene CD19 and neoplasm.